Current use of hydroxychloroquine was associated with a significantly decreased risk for cardiovascular events among patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE),
HCQ associated with lower platelet activity and improved vascular health
New test method can offer safer dosages of hydroxychloroquine
Researchers have developed a new method to measure levels of the anti-malarial drug hydroxychloroquine (HCQ) in patients with lupus.
A disadvantage of hydroxychloroquine is its side effects which can be avoided, however, if the dosage is adjusted for each patient, said the study researchers from Uppsala University in Sweden.
High Doses of Hydroxychloroquine May Protect Against Thrombosis in SLE
Higher prescribed doses of hydroxychloroquine (HCQ) may be associated with lower odds of thrombotic events in patients with systemic lupus erythematosus (SLE), according to study results presented at the 2019 The American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, held November 8 to 13, 2019, in Atlanta, Georgia.
